Vaccines for viral and bacterial pathogens causing acute gastroenteritis: Part II: Vaccines for Shigella, Salmonella, enterotoxigenic E. coli (ETEC) enterohemorragic E. coli (EHEC) and Campylobacter jejuni

References

• Hale TL. Genetic basis of virulence in Shigella species. Microbiol Rev 1991; 55:206-24; PMID:1886518.
   PubMedGoogle Scholar
• Shiga K. The trend of prevention, therapy and epidemiology of dysentery since the discovery of its causative organism. New Engl J Med 1936; 215:1205-11; http://dx.doi.org/10.1056/NEJM193612242152602
   Google Scholar
• Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine MM. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999; 77:651-66; PMID:10516787
   PubMed Web of Science ®Google Scholar
• Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu Y, Sow SO, Sur D, Breiman RF, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 2013; 382:209-22; PMID:23680352; http://dx.doi.org/10.1016/S0140-6736(13)60844-2
   PubMed Web of Science ®Google Scholar
• Schroeder GN, Hilbi H. Molecular pathogenesis of Shigella spp.: controlling host cell signaling, invasion, and death by type III secretion. Clin Microbiol Rev 2008; 21:134-56; PMID:18202440; http://dx.doi.org/10.1128/CMR.00032-07
   PubMed Web of Science ®Google Scholar
• Parsot C. Shigella spp. and enteroinvasive Escherichia coli pathogenicity factors. FEMS Microbiol Lett 2005; 252:11-8; PMID:16182469; http://dx.doi.org/10.1016/j.femsle.2005.08.046
   PubMed Web of Science ®Google Scholar
• Bhattacharya D, Bhattacharya H, Sayi DS, Bharadwaj AP, Singhania M, Sugunan AP, Roy S. Changing patterns and widening of antibiotic resistance in Shigella spp. over a decade (2000-2011), Andaman Islands, India. Epidemiol Infect 2014:1-8; PMID:24763083; http://dx.doi.org/10.1017/S0950268814000958
   PubMedGoogle Scholar
• Gu B, Ke X, Pan S, Cao Y, Zhuang L, Yu R, Qian H, Liu G, Tong M. Prevalence and trends of aminoglycoside resistance in Shigella worldwide, 1999-2010. J Biomed Res 2013; 27:103-15; PMID:23554801; http://dx.doi.org/10.7555/JBR.27.20120125
   PubMedGoogle Scholar
• Kosek M, Yori PP, Olortegui MP. Shigellosis update: advancing antibiotic resistance, investment empowered vaccine development, and green bananas. Curr Opin Infect Dis 2010; 23:475-80; PMID:20689423; http://dx.doi.org/10.1097/QCO.0b013e32833da204
   PubMed Web of Science ®Google Scholar
• Marcoleta A, Toro C, Prado V, Serrano M, Fernandez P, Benadof D, Camponovo R, Campos V, Porte L, Zamorano J, et al. Antibiotic susceptibility patterns among Shigella sonnei, isolated during three different periods in Region Metropolitana, Chile. Rev Chilena Infectol 2013; 30:616-21; PMID:24522304; http://dx.doi.org/10.4067/S0716-10182013000600007
   PubMedGoogle Scholar
• DuPont HL, Levine MM, Hornick RB, Formal SB. Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 1989; 159:1126-8; PMID:2656880; http://dx.doi.org/10.1093/infdis/159.6.1126
   PubMed Web of Science ®Google Scholar
• Kim YJ, Yeo SG, Park JH, Ko HJ. Shigella vaccine development: prospective animal models and current status. Curr Pharm Biotechnol 2014; 14:903-12; PMID:24372251; http://dx.doi.org/10.2174/1389201014666131226123900
   PubMedGoogle Scholar
• Barman S, Saha DR, Ramamurthy T, Koley H. Development of a new guinea-pig model of shigellosis. FEMS Immunol Med Microbiol 2011; 62:304-14; PMID:21539623; http://dx.doi.org/10.1111/j.1574-695X.2011.00810.x
   PubMedGoogle Scholar
• Islam D, Ruamsap N, Khantapura P, Aksomboon A, Srijan A, Wongstitwilairoong B, Bodhidatta L, Gettayacamin M, Venkatesan MM, Mason CJ. Evaluation of an intragastric challenge model for Shigella dysenteriae 1 in rhesus monkeys (Macaca mulatta) for the pre-clinical assessment of Shigella vaccine formulations. APMIS 2014; 122:463-75; PMID:24028276; http://dx.doi.org/10.1111/apm.12168
   PubMedGoogle Scholar
• Gregory M KR, Lugo-Roman LA, Galvez Carrillo H, Tilley DH, Baldeviano C, Simons MP, Reynolds ND, Ranallo RT, Suvarnapunya AE, Venkatesan MM, et al. Development of an Aotus nancymaae model for Shigella Vaccine immunogenicity and efficacy studies. Infect Immun 2014; 82:2027-36; PMID:24595138; http://dx.doi.org/10.1128/IAI.01665-13
   PubMed Web of Science ®Google Scholar
• Yang JY, Lee SN, Chang SY, Ko HJ, Ryu S, Kweon MN. A mouse model of shigellosis by intraperitoneal infection. J Infect Dis 2014; 209:203-15; PMID:23904297; http://dx.doi.org/10.1093/infdis/jit399
   PubMedGoogle Scholar
• Taylor DN, Trofa AC, Sadoff J, Chu C, Bryla D, Shiloach J, Cohen D, Ashkenazi S, Lerman Y, Egan W. Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoids. Infect Immun 1993; 61:3678-87; PMID:8359890
   PubMed Web of Science ®Google Scholar
• Ashkenazi S, Passwell JH, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla DA, Karpas AB, et al. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J Infect Dis 1999; 179:1565-8; PMID:10228084; http://dx.doi.org/10.1086/314759
   PubMed Web of Science ®Google Scholar
• Passwell JH, Ashkenazi S, Harlev E, Miron D, Ramon R, Farzam N, Lerner-Geva L, Levi Y, Chu C, Shiloach J, et al. Israel Shigella Study G. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children. Pediatr Infect Dis J 2003; 22:701-6; PMID:12913770; http://dx.doi.org/10.1097/01.inf.0000078156.03697.a5
   PubMed Web of Science ®Google Scholar
• Passwell J, Harlev E, Ashkenazi S, Chu C, Miron D, Ramon R, Farzan N, Shiloach J, Bryla D, Majadly F, et al. Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel. Infect Immun 2001; 69:1351-7; PMID:11179298; http://dx.doi.org/10.1128/IAI.69.3.1351-1357.2001
   PubMed Web of Science ®Google Scholar
• Chowers Y, Kirschner J, Keller N, Barshack I, Bar-Meir S, Ashkenazi S, Schneerson R, Robbins J, Passwell JH. O-specific polysaccharide conjugate vaccine-induced antibodies prevent invasion of Shigella into Caco-2 cells and may be curative. Proc Natl Acad Sci USA 2007; 104:2396-401; PMID:17287349
   PubMed Web of Science ®Google Scholar
• Passwell JH, Ashkenzi S, Banet-Levi Y, Ramon-Saraf R, Farzam N, Lerner-Geva L, Even-Nir H, Yerushalmi B, Chu C, Shiloach J, et al. Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. Vaccine 2010; 28:2231-5; PMID:20056180; http://dx.doi.org/10.1016/j.vaccine.2009.12.050
   PubMed Web of Science ®Google Scholar
• Barzu S, Fontaine A, Sansonetti P, Phalipon A. Induction of a local anti-IpaC antibody response in mice by use of a Shigella flexneri 2a vaccine candidate: implications for use of IpaC as a protein carrier. Infect Immun 1996; 64:1190-6; PMID:8606077
   PubMed Web of Science ®Google Scholar
• Coster TS, Hoge CW, VanDeVerg LL, Hartman AB, Oaks EV, Venkatesan MM, Cohen D, Robin G, Fontaine-Thompson A, Sansonetti PJ, et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 1999; 67:3437-43; PMID:10377124
   PubMed Web of Science ®Google Scholar
• Katz DE, Coster TS, Wolf MK, Trespalacios FC, Cohen D, Robins G, Hartman AB, Venkatesan MM, Taylor DN, Hale TL. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 2004; 72:923-30; PMID:14742537; http://dx.doi.org/10.1128/IAI.72.2.923-930.2004
   PubMed Web of Science ®Google Scholar
• Rahman KM, Arifeen SE, Zaman K, Rahman M, Raqib R, Yunus M, Begum N, Islam MS, Sohel BM, Rahman M, et al. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine 2011; 29:1347-54; PMID:21040694; http://dx.doi.org/10.1016/j.vaccine.2010.10.035
   PubMed Web of Science ®Google Scholar
• Launay O, Sadorge C, Jolly N, Poirier B, Bechet S, Van der Vliet D, Seffer V, Fenner N, Dowling K, Giemza R, et al. Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial. Vaccine 2009; 27:1184-91; PMID:19135496; http://dx.doi.org/10.1016/j.vaccine.2008.12.021
   PubMedGoogle Scholar
• Sadorge C, Ndiaye A, Beveridge N, Frazer S, Giemza R, Jolly N, Johnson J, Liddy H, Cosgrove CA, Allavena P, et al. Phase 1 clinical trial of live attenuated Shigella dysenteriae type-1 DicsA Dent Dfep DstxA:HgR oral vaccine SC599 in healthy human adult volunteers. Vaccine 2008; 26:978-87; PMID:18207287; http://dx.doi.org/10.1016/j.vaccine.2007.11.024
   PubMedGoogle Scholar
• Hartman AB, Venkatesan MM. Construction of a stable attenuated Shigella sonnei DvirG vaccine strain, WRSS1, and protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Infect Immun 1998; 66:4572-6; PMID:9712824
   PubMed Web of Science ®Google Scholar
• Kotloff KLTD, Sztein MB, Wasserman SS, Losonsky GA, Nataro JP, Venkatesan M, Hartman A, Picking WD, Katz DE, Campbell JD, et al. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 2002; 70:2016-21; PMID:11895966; http://dx.doi.org/10.1128/IAI.70.4.2016-2021.2002
   PubMed Web of Science ®Google Scholar
• Orr N, Katz D, Atsmon J, Radu P, Yavzori M, Halperin T, Sela T, Kayouf R, Klein Z, Ambar R, et al. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun 2005; 73:8027-32; PMID:16299296; http://dx.doi.org/10.1128/IAI.73.12.8027-8032.2005
   PubMed Web of Science ®Google Scholar
• Venkatesan M. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Infect Immun 2002; 70:2950-8; PMID:12010984; http://dx.doi.org/10.1128/IAI.70.6.2950-2958.2002
   PubMedGoogle Scholar
• McKenzie R, Venkatesan M, Wolf M, Islam D, Grahek S, Jones A, Bloom A, Taylor D, Hale T, Bourgeois A. Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate. Vaccine 2008; 26:3291-6; PMID:18468742; http://dx.doi.org/10.1016/j.vaccine.2008.03.079
   PubMedGoogle Scholar
• Chu C, Liu B, Watson D, Szu S, Bryla D, Shiloach J, Schneerson R, Robbins JB. Preparation, characterization, and immunogenicity of conjugates composed of the O-specific polysaccharide of Shigella dysenteriae type 1 (Shiga's bacillus) bound to tetanus toxoid. Infect Immun 1991; 59:4450-8; PMID:1937803
   PubMed Web of Science ®Google Scholar
• Pozsgay V. Recent developments in synthetic oligosaccharide-based bacterial vaccines. Curr Top Med Chem 2008; 8:126-40; PMID:18289082; http://dx.doi.org/10.2174/156802608783378864
   PubMed Web of Science ®Google Scholar
• Phalipon A, Costachel C, Grandjean C, Thuizat A, Guerreiro C, Tanguy M, Nato F, Vulliez-Le Normand B, Bélot F, Wright K, et al. Characterization of functional oligosaccharide mimics of the Shigella flexneri serotype 2a O-antigen: Implications for the development of a chemically defined glycoconjugate vaccine. J Immunol 2006; 176:1686-94; PMID:16424198; http://dx.doi.org/10.4049/jimmunol.176.3.1686
   PubMed Web of Science ®Google Scholar
• Phalipon A, Tanguy M, Grandjean C, Guerreiro C, Bélot F, Cohen D, Sansonetti P, Mulard L. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J Immunol 2009; 182:2241-7; PMID:19201878; http://dx.doi.org/10.4049/jimmunol.0803141
   PubMed Web of Science ®Google Scholar
• Pozsgay V, Chu C, Pannell L, Wolfe J, Robbins JB, Schneerson R. Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1. Proc Natl Acad Sci USA 1999; 96:5194-7; PMID:10220442
   PubMed Web of Science ®Google Scholar
• Robbins J, Kubler-Kielb J, Vinogradov E, Mocca C, Pozsgay V, Shiloach J, Schneerson R. Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates. Proc Natl Acad Sci USA 2009; 106:7974-8; PMID:19346477; http://dx.doi.org/10.1073/pnas.0900891106
   PubMed Web of Science ®Google Scholar
• Turbyfill K, Hartman A, Oaks E. Isolation and characterization of a Shigella flexneri invasin complex subunit vaccine. Infect Immun 2000; 68:6624-32; PMID:11083774; http://dx.doi.org/10.1128/IAI.68.12.6624-6632.2000
   PubMed Web of Science ®Google Scholar
• Oaks E, Turbyfill K. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (Invaplex) vaccine. Vaccine 2006; 24:2290-301; PMID:16364513; http://dx.doi.org/10.1016/j.vaccine.2005.11.040
   PubMed Web of Science ®Google Scholar
• Riddle M, Kaminski R, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, et al. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine 2011; 29:7009-19; PMID:21787825; http://dx.doi.org/10.1016/j.vaccine.2011.07.033
   PubMed Web of Science ®Google Scholar
• Tribble D, Kaminski R, Cantrell J, Nelson M, Porter C, Baqar S, Williams C, Arora R, Saunders J, Ananthakrishnan M, et al. Safety and immunogenicity of a Shigella flexneri 2a Invaplex 50 intranasal vaccine in adult volunteers. Vaccine 2010; 28:6076-85; PMID:20619378; http://dx.doi.org/10.1016/j.vaccine.2010.06.086
   PubMedGoogle Scholar
• Heine SJ, Diaz-McNair J, Andar AU, Drachenberg CB, Van De Verg LL, Walker R, Picking WL, Pasetti MF. Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes. J Immunol 2014; 192:1630-40; PMID:24453241; http://dx.doi.org/10.4049/jimmunol.1302743
   PubMed Web of Science ®Google Scholar
• Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, Picking WD, Van De Verg LL, Walker RI, Picking WL. Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine. Infect Immun 2013; 81:4470-7; PMID:24060976; http://dx.doi.org/10.1128/IAI.00859-13
   PubMedGoogle Scholar
• McKenzie R, Walker RI, Nabors GS, Van De Verg LL, Carpenter C, Gomes G, Forbes E, Tian JH, Yang HH, Pace JL, et al. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine 2006; 24:3735-45; PMID:16095766; http://dx.doi.org/10.1016/j.vaccine.2005.07.014
   PubMed Web of Science ®Google Scholar
• Kaminski RW, Wu M, Turbyfill KR, Clarkson K, Tai B, Bourgeois AL, Van De Verg LL, Walker RI, Oaks EV. Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. Clin Vaccine Immunol 2014; 21:366-82; PMID:24403527; http://dx.doi.org/10.1128/CVI.00683-13
   PubMedGoogle Scholar
• Barman S, Koley H, Nag D, Shinoda S, Nair GB, Takeda Y. Passive immunity with multi-serotype heat-killed Shigellae in neonatal mice. Microbiol Immunol 2014; 58:463-6; PMID:24909404; http://dx.doi.org/10.1111/1348-0421.12164
   PubMedGoogle Scholar
• Ranallo RT, Thakkar S, Chen Q, Venkatesan MM. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. Vaccine 2007; 25:2269-78; PMID:17229494; http://dx.doi.org/10.1016/j.vaccine.2006.11.067
   PubMed Web of Science ®Google Scholar
• D'Hauteville H, Khan S, Maskell DJ, Kussak A, Weintraub A, Mathison J, Ulevitch RJ, Wuscher N, Parsot C, Sansonetti PJ. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 2002; 168:5240-51; PMID:11994481; http://dx.doi.org/10.4049/jimmunol.168.10.5240
   PubMed Web of Science ®Google Scholar
• Ranallo R, Fonseka S, Boren T, Bedford L, Kaminski R, Thakkar S, Venkatesan M. Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates. Vaccine 2012; 30:5159-71; PMID:22658966; http://dx.doi.org/10.1016/j.vaccine.2012.05.003
   PubMedGoogle Scholar
• Ranallo RT, Kaminski R, Baqar S, Dutta M, Lugo-Roman LA, Boren T, Barnoy S, Venkatesan MM. Oral administration of live Shigella vaccine candidates in rhesus monkeys show no evidence of competition for colonization and immunogenicity between different serotypes. Vaccine 2014; 32:1754-60; PMID:24522159; http://dx.doi.org/10.1016/j.vaccine.2013.12.068
   PubMedGoogle Scholar
• Barnoy S, Jeong KI, Helm RF, Suvarnapunya AE, Ranallo RT, Tzipori S, Venkatesan MM. Characterization of WRSs2 and WRSs3, new second-generation virG (icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity. Vaccine 2010; 28:1642-54; PMID:19932216; http://dx.doi.org/10.1016/j.vaccine.2009.11.001
   PubMedGoogle Scholar
• Barnoy S, Baqar S, Kaminski RW, Collins T, Nemelka K, Hale TL, Ranallo RT, Venkatesan MM. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. Vaccine 2011; 29:6371-8; PMID:21596086; http://dx.doi.org/10.1016/j.vaccine.2011.04.115
   PubMed Web of Science ®Google Scholar
• Acevedo R, Fernandez S, Zayas C, Acosta A, Sarmiento ME, Ferro VA, Rosenqvist E, Campa C, Cardoso D, Garcia L, et al. Bacterial outer membrane vesicles and vaccine applications. Front Immunol 2014; 5:121; PMID:24715891; http://dx.doi.org/10.3389/fimmu.2014.00121
   PubMed Web of Science ®Google Scholar
• Camacho AI, Souza-Reboucas J, Irache JM, Gamazo C. Towards a non-living vaccine against Shigella flexneri: from the inactivation procedure to protection studies. Methods 2013; 60:264-8; PMID:23046911; http://dx.doi.org/10.1016/j.ymeth.2012.09.008
   PubMedGoogle Scholar
• Brenner FW, Villar RG, Angulo FJ, Tauxe R, Swaminathan B. Salmonella nomenclature. J Clin Microbiol 2000; 38:2465-7; PMID:10878026
   PubMed Web of Science ®Google Scholar
• Canals R, McClelland M, Santiviago C, Andrews-Polymenis H. Genomics of Salmonella species. In: Wiedmann M, Zhang W, eds. Genomics of Foodborne Bacterial Pathogens, New York: Springer, 2011, 171-235.
   Google Scholar
• MacLennan CA, Martin LB, Micoli F. Vaccines against invasive Salmonella disease. Hum Vaccin Immunother 2014; 10:1-16; PMID:24832715; http://dx.doi.org/10.4161/hv.29054
   PubMedGoogle Scholar
• Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, Jones TF, Fazil A, Hoekstra RM. The global burden of nontyphoidal Salmonella gastroenteritis. Clin Infect Dis 2010; 50:882-9; PMID:20158401; http://dx.doi.org/10.1086/650733
   PubMed Web of Science ®Google Scholar
• Christenson JC. Salmonella infections. Pediatr Rev 2013; 34:375-83; PMID:24000341; http://dx.doi.org/10.1542/pir.34-9-375
   PubMedGoogle Scholar
• Santos RL. Pathobiology of salmonella, intestinal microbiota, and the host innate immune response. Front Immunol 2014; 5:252-; PMID:24904595; http://dx.doi.org/10.3389/fimmu.2014.00252
   PubMed Web of Science ®Google Scholar
• Hindle ZCS, Phillimore J, Bentley M, Johnson J, Cosgrove CA, Ghaem-Maghami M, Sexton A, Khan M, Brennan FR, Everest P, et al. Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect Immun 2002; 70:3457-67; PMID:12065485; http://dx.doi.org/10.1128/IAI.70.7.3457-3467.2002
   PubMed Web of Science ®Google Scholar
• Simon R, Levine M. Glycoconjugate vaccine strategies for protection against invasive Salmonella infections. Hum Vaccines Immunother 2012; 8:494-8; PMID:22370510; http://dx.doi.org/10.4161/hv.19158
   PubMed Web of Science ®Google Scholar
• Watson DC, Robbins JB, Szu SC. Protection of mice against Salmonella typhimurium with an O-specific polysaccharide-protein conjugate vaccine. Infect Immun 1992; 60:4679-86; PMID:1383154
   PubMed Web of Science ®Google Scholar
• Svenson SB, Nurminen M, Lindberg AC. Artificial Salmonella vaccines: O-antigenic oligosaccharide-protein conjugates induce protection against infection with Salmonella typhimurium. Infect Immun 1979; 25:863-72; PMID:387597
   PubMed Web of Science ®Google Scholar
• Svenson SB, Lindberg AC. Artificial Salmonella vaccines: Salmonella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice. Infect Immun 1981; 32:490-6; PMID:6166555
   PubMed Web of Science ®Google Scholar
• Stefanetti G, Rondini S, Lanzilao L, Saul A, MacLennan C, Micoli F. Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines. Vaccine 2014; 32:6122-9; PMID:25192974; http://dx.doi.org/10.1016/j.vaccine.2014.08.056
   PubMed Web of Science ®Google Scholar
• Simon R, Tennant SM, Wang JY, Schmidlein PJ, Lees A, Ernst RK, Pasetti MF, Galen JE, Levine MM. Salmonella enterica serovar Enteritidis core O polysaccharide conjugated to H:g,m flagellin as a candidate vaccine for protection against invasive infection with S. Enteritidis. Infect Immun 2011; 79:4240-9; PMID:21807909; http://dx.doi.org/10.1128/IAI.05484-11
   PubMed Web of Science ®Google Scholar
• Simon R, Wang J, Boyd M, Tulapurkar M, Ramachandran G, Tennant S, Pasetti M, Galen J, Levine M. Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates. PLoS One 2013; 8:e64680; PMID:23741368; http://dx.doi.org/10.1371/journal.pone.0064680
   PubMed Web of Science ®Google Scholar
• Pasquali P, Ammendola S, Pistoia C, Petrucci P, Tarantino M, Valente C, Marenzoni M, Rotilio G, Battistoni A. Attenuated Salmonella enterica serovar Typhimurium lacking the ZnuABC transporter confers immune-based protection against challenge infections in mice. Vaccine 2008; 26:3421-6; PMID:18499306; http://dx.doi.org/10.1016/j.vaccine.2008.04.036
   PubMedGoogle Scholar
• Pesciaroli M, Aloisio F, Ammendola S, Pistoia C, Petrucci P, Tarantino M, Francia M, Battistoni A, Pasquali P. An attenuated Salmonella enterica serovar Typhimurium strain lacking the ZnuABC transporter induces protection in a mouse intestinal model of Salmonella infection. Vaccine 2011; 29:1783-90; PMID:21219981; http://dx.doi.org/10.1016/j.vaccine.2010.12.111
   PubMed Web of Science ®Google Scholar
• Allam U, Krishna M, Lahiri A, Joy O, Chakravortty D. Salmonella enterica Serovar Typhimurium lacking hfq gene confers protective immunity against murine typhoid. PLoS One 2011; 6:e16667; PMID:21347426; http://dx.doi.org/10.1371/journal.pone.0016667
   PubMedGoogle Scholar
• Vishwakarma V, Pati N, Chandel H, Sahoo S, Saha B, Suar M. Evaluation of Salmonella enterica serovar Typhimurium TTSS-2 deficient fur mutant as safe live-attenuated vaccine candidate for immunocompromised mice. PLoS One 2012; 7:e52043; PMID:23284865; http://dx.doi.org/10.1371/journal.pone.0052043
   PubMedGoogle Scholar
• Tennant SM, Wang J-Y, Galen JE, Simon R, Pasetti MF, Gat O, Levine MM. Engineering and preclinical evaluation of attenuated nontyphoidal Salmonella strains serving as live oral vaccines and as reagent strains. Infect Immun 2011; 79:4175-85; PMID:21807911; http://dx.doi.org/10.1128/IAI.05278-11
   PubMed Web of Science ®Google Scholar
• Ochoa-Repáraz J, García B, Solano C, Lasa I, Irache J, Gamazo C. Protective ability of subcellular extracts from Salmonella Enteritidis and from a rough isogenic mutant against salmonellosis in mice. Vaccine 2005; 23:1491-501; PMID:15670885; http://dx.doi.org/10.1016/j.vaccine.2004.09.016
   PubMed Web of Science ®Google Scholar
• Jawale CV, Lee JH. Characterization of adaptive immune responses induced by a new genetically inactivated Salmonella Enteritidis vaccine. Comp Immunol Microbiol Infect Dis 2014; 37:159-67; PMID:24878070; http://dx.doi.org/10.1016/j.cimid.2014.05.001
   PubMed Web of Science ®Google Scholar
• Sanchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. Curr Opin Immunol 2005; 17:388-98; PMID:15963708; http://dx.doi.org/10.1016/j.coi.2005.06.007
   PubMed Web of Science ®Google Scholar
• Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev 2013; 26:822-80; PMID:24092857; http://dx.doi.org/10.1128/CMR.00022-13
   PubMed Web of Science ®Google Scholar
• Gaastra W, Svennerholm AM. Colonization factors of human enterotoxigenic Escherichia coli (ETEC). Trends Microbiol 1996; 4:444-52; PMID:8950814; http://dx.doi.org/10.1016/0966-842X(96)10068-8
   PubMed Web of Science ®Google Scholar
• Isidean SD, Riddle MS, Savarino SJ, Porter CK. A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. Vaccine 2011; 29:6167-78; PMID:21723899; http://dx.doi.org/10.1016/j.vaccine.2011.06.084
   PubMed Web of Science ®Google Scholar
• Svennerholm AM, Lundgren A. Recent progress toward an enterotoxigenic Escherichia coli vaccine. Expert Rev Vaccines 2012; 11:495-507; PMID:22551034; http://dx.doi.org/10.1586/erv.12.12
   PubMed Web of Science ®Google Scholar
• Organization WH. Oral cholera vaccine stockpile for cholera emergency response. [Internet] 09/16/2013. Available from http://www.who.int/cholera/vaccines/Briefing_OCV_stockpile.pdf?ua=1
   Google Scholar
• Clemens JD, Sack DA, Harris JR, Chakraborty J, Neogy PK, Stanton B, Huda N, Khan MU, Kay BA, Khan MR. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 1988; 158:372-7; PMID:3042876; http://dx.doi.org/10.1093/infdis/158.2.372
   PubMed Web of Science ®Google Scholar
• Peltola H, Siitonen A, Kyronseppa H, Simula I, Mattila L, Oksanen P, Kataja MJ, Cadoz M. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991; 338:1285-9; PMID:1682684; http://dx.doi.org/10.1016/0140-6736(91)92590-X
   PubMed Web of Science ®Google Scholar
• Scerpella EG, Sanchez JL, Mathewson, III, Torres-Cordero JV, Sadoff JC, Svennerholm AM, DuPont HL, Taylor DN, Ericsson CD. Safety, Immunogenicity, and Protective Efficacy of the Whole-Cell/Recombinant B Subunit (WC/rBS) Oral Cholera Vaccine Against Travelers' Diarrhea. J Travel Med 1995; 2:22-7; PMID:9815355; http://dx.doi.org/10.1111/j.1708-8305.1995.tb00615.x
   PubMedGoogle Scholar
• Crucell. Dukoral. When to take Dukoral® for traveller's diarrhea [Internet] 2014 [Last Updated October 2014]. Available from http://www.dukoralcanada.com/when-to-take-dukoral
   Google Scholar
• Ahmed T BT, Zaman K, Sinclair D, Qadri F. Vaccines for preventing enterotoxigenic Escherichia coli (ETEC) diarrhoea. Cochrane Database Syst Rev 2013; 7:CD009029; PMID:23828581
   PubMed Web of Science ®Google Scholar
• Behrens RH, Cramer JP, Jelinek T, Shaw H, von Sonnenburg F, Wilbraham D, Weinke T, Bell DJ, Asturias E, Pauwells HLE, et al. Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala. Lancet Infect Dis 2014; 14:197-204; PMID:24291168; http://dx.doi.org/10.1016/S1473-3099(13)70297-4
   PubMed Web of Science ®Google Scholar
• Darsley MJ, Chakraborty S, DeNearing B, Sack DA, Feller A, Buchwaldt C, Bourgeois AL, Walker R, Harro CD. The oral, live attenuated enterotoxigenic Escherichia coli vaccine ACE527 reduces the incidence and severity of diarrhea in a human challenge model of diarrheal disease. Clin Vaccine Immunol 2012; 19:1921-31; PMID:23035175; http://dx.doi.org/10.1128/CVI.00364-12
   PubMed Web of Science ®Google Scholar
• Otto W, Najnigier B, Stelmasiak T, Robins-Browne RM. Randomized control trials using a tablet formulation of hyperimmune bovine colostrum to prevent diarrhea caused by enterotoxigenic Escherichia coli in volunteers. Scand J Gastroenterol 2011; 46:862-8; PMID:21526980; http://dx.doi.org/10.3109/00365521.2011.574726
   PubMed Web of Science ®Google Scholar
• Jertborn M, Ahren C, Holmgren J, Svennerholm AM. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. Vaccine 1998; 16:255-60; PMID:9607039; http://dx.doi.org/10.1016/S0264-410X(97)00169-2
   PubMed Web of Science ®Google Scholar
• Qadri F, Wenneras C, Ahmed F, Asaduzzaman M, Saha D, Albert MJ, Sack RB, Svennerholm A. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. Vaccine 2000; 18:2704-12; PMID:10781858; http://dx.doi.org/10.1016/S0264-410X(00)00056-6
   PubMed Web of Science ®Google Scholar
• Savarino SJ, Brown FM, Hall E, Bassily S, Youssef F, Wierzba T, Peruski L, El-Masry NA, Safwat M, Rao M, et al. Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults. J Infect Dis 1998; 177:796-9; PMID:9498468; http://dx.doi.org/10.1086/517812
   PubMed Web of Science ®Google Scholar
• Wiedermann G, Kollaritsch H, Kundi M, Svennerholm AM, Bjare U. Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report). J Travel Med 2000; 7:27-9; PMID:10689236; http://dx.doi.org/10.2310/7060.2000.00007
   PubMed Web of Science ®Google Scholar
• Sack DA, Shimko J, Torres O, Bourgeois AL, Francia DS, Gustafsson B, Karnell A, Nyquist I, Svennerholm A-M. Randomised, double-blind, safety and efficacy of a killed oral vaccine for enterotoxigenic E. coli diarrhoea of travellers to Guatemala and Mexico. Vaccine 2007; 25:4392-400; PMID:17448578; http://dx.doi.org/10.1016/j.vaccine.2007.03.034
   PubMed Web of Science ®Google Scholar
• Tobias J, Svennerholm A-M. Strategies to overexpress enterotoxigenic Escherichia coli (ETEC) colonization factors for the construction of oral whole-cell inactivated ETEC vaccine candidates. Appl Microbiol Biotechnol 2012; 93:2291-300; PMID:22350259; http://dx.doi.org/10.1007/s00253-012-3930-6
   PubMed Web of Science ®Google Scholar
• Lundgren A, Leach S, Tobias J, Carlin N, Gustafsson B, Jertborn M, Bourgeois L, Walker R, Holmgren J, Svennerholm AM. Clinical trial to evaluate safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli prototype vaccine containing CFA/I overexpressing bacteria and recombinantly produced LTB/CTB hybrid protein. Vaccine 2013; 31:1163-70; PMID:23306362; http://dx.doi.org/10.1016/j.vaccine.2012.12.063
   PubMed Web of Science ®Google Scholar
• McKenzie R, Darsley M, Thomas N, Randall R, Carpenter C, Forbes E, Finucane M, Sack RB, Hall E, Bourgeois AL. A double-blind, placebo-controlled trial to evaluate the efficacy of PTL-003, an attenuated enterotoxigenic E. coli (ETEC) vaccine strain, in protecting against challenge with virulent ETEC. Vaccine 2008; 26:4731-9; PMID:18602960; http://dx.doi.org/10.1016/j.vaccine.2008.06.064
   PubMed Web of Science ®Google Scholar
• Lapa JA, Sincock SA, Ananthakrishnan M, Porter CK, Cassels FJ, Brinkley C, Hall ER, Van Hamont J, Gramling JD, Carpenter CM, et al. Randomized clinical trial assessing the safety and immunogenicity of oral microencapsulated enterotoxigenic Escherichia coli surface antigen 6 with or without heat-labile enterotoxin with mutation R192G. Clin Vaccine Immunol 2008; 15:1222-8; PMID:18579693; http://dx.doi.org/10.1128/CVI.00491-07
   PubMedGoogle Scholar
• Guerena-Burgueño F, Hall ER, Taylor DN, Cassels FJ, Scott DA, Wolf MK, Roberts ZJ, Nesterova GV, Alving CR, Glenn GM. Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immun 2002; 70:1874-80; PMID:Can't; http://dx.doi.org/10.1128/IAI.70.4.1874-1880.2002
   PubMed Web of Science ®Google Scholar
• El-Kamary SS, Cohen MB, Bourgeois AL, Van De Verg L, Bauers N, Reymann M, Pasetti MF, Chen WH. Safety and immunogenicity of a single oral dose of recombinant double mutant heat-labile toxin derived from enterotoxigenic Escherichia coli. Clin Vaccine Immunol 2013; 20:1764-70; PMID:24049109; http://dx.doi.org/10.1128/CVI.00464-13
   PubMedGoogle Scholar
• Holmgren J, Bourgeois L, Carlin N, Clements J, Gustafsson B, Lundgren A, Nygren E, Tobias J, Walker R, Svennerholm AM. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant. Vaccine 2013; 31:2457-64; PMID:23541621; http://dx.doi.org/10.1016/j.vaccine.2013.03.027
   PubMed Web of Science ®Google Scholar
• Barry EM, Wang J, Wu T, Davis T, Levine MM. Immunogenicity of multivalent Shigella-ETEC candidate vaccine strains in a guinea pig model. Vaccine 2006; 24:3727-34; PMID:16169130; http://dx.doi.org/10.1016/j.vaccine.2005.07.013
   PubMed Web of Science ®Google Scholar
• Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, Killeen KP. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic Escherichia coli. Vaccine 2007; 25:8574-84; PMID:18045752; http://dx.doi.org/10.1016/j.vaccine.2007.09.074
   PubMed Web of Science ®Google Scholar
• Ruan X, Robertson DC, Nataro JP, Clements JD, Zhang W. Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing Anti-STa antibodies. Infect Immun 2014; 82:1823-32; PMID:24549325; http://dx.doi.org/10.1128/IAI.01394-13
   PubMed Web of Science ®Google Scholar
• Roy K BS, Qadri F, Fleckenstein JM. Enterotoxigenic Escherichia coli elicits immune responses to multiple surface proteins. Infect Immun 2010; 78:3027-35; PMID:20457787; http://dx.doi.org/10.1128/IAI.00264-10
   PubMed Web of Science ®Google Scholar
• Roy K HG, Hamilton DJ, Luo J, Ostmann MM, Fleckenstein JM. Enterotoxigenic Escherichia coli EtpA mediates adhesion between flagella and host cells. Infect Immun 2009; 457:594-8
   Google Scholar
• Del Canto F, Valenzuela P, Cantero L, Bronstein J, Blanco JE, Blanco J, Prado V, Levine M, Nataro J, Sommerfelt H, et al. Distribution of classical and nonclassical virulence genes in enterotoxigenic Escherichia coli isolates from Chilean children and tRNA gene screening for putative insertion sites for genomic islands. J Clin Microbiol 2011; 49:3198-203; PMID:21775541; http://dx.doi.org/10.1128/JCM.02473-10
   PubMed Web of Science ®Google Scholar
• Harris JA RK, Woo-Rasberry V, Hamilton DJ, Kansal R, Qadri F, Fleckenstein JM. Directed evaluation of enterotoxigenic Escherichia coli autotransporter proteins as putative vaccine candidates. PLoS Negl Trop Dis 2011; 5:e1428; PMID:22163060; http://dx.doi.org/10.1371/journal.pntd.0001428
   PubMed Web of Science ®Google Scholar
• Roy K HD, Allen KP, Randolph MP, Fleckenstein JM. The EtpA exoprotein of enterotoxigenic Escherichia coli promotes intestinal colonization and is a protective antigen in an experimental model of murine infection. Infect Immun 2008; 76:2106-12; PMID:18285493; http://dx.doi.org/10.1128/IAI.01304-07
   PubMed Web of Science ®Google Scholar
• Riley LW, Remis RS, Helgerson SD, McGee HB, Wells JG, Davis BR, Hebert RJ, Olcott ES, Johnson LM, Hargrett NT, et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983; 308:681-5; PMID:6338386; http://dx.doi.org/10.1056/NEJM198303243081203
   PubMed Web of Science ®Google Scholar
• Karmali MA, Petric M, Lim C, Fleming PC, Steele BT. Escherichia coli cytotoxin, haemolytic-uraemic syndrome, and haemorrhagic colitis. Lancet 1983; 2:1299-300; PMID:6139632; http://dx.doi.org/10.1016/S0140-6736(83)91167-4
   PubMed Web of Science ®Google Scholar
• Konowalchuk J, Speirs JI, Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun 1977; 18:775-9; PMID:338490
   PubMed Web of Science ®Google Scholar
• McKee ML, Melton-Celsa AR, Moxley RA, Francis DH, O'Brien AD. Enterohemorrhagic Escherichia coli O157:H7 requires intimin to colonize the gnotobiotic pig intestine and to adhere to HEp-2 cells. Infect Immun 1995; 63:3739-44; PMID:7642319
   PubMed Web of Science ®Google Scholar
• Moon HW, Whipp SC, Argenzio RA, Levine MM, Giannella RA. Attaching and effacing activities of rabbit and human enteropathogenic Escherichia coli in pig and rabbit intestines. Infect Immun 1983; 41:1340-51; PMID:6350186
   PubMed Web of Science ®Google Scholar
• Nataro JP, Kaper JB. Diarrheagenic Escherichia coli. Clin Microbiol Rev 1998; 11:142-201; PMID:9457432
   PubMed Web of Science ®Google Scholar
• Consensus conference statement: Escherichia coli O157:H7 infections–an emerging national health crisis, July 11-13, 1994. Gastroenterology 1995; 108:1923-34; PMID:7768399; http://dx.doi.org/10.1016/0016-5085(95)90159-0
   PubMedGoogle Scholar
• Prado JV, Cavagnaro SMF. Hemolytic uremic syndrome associated to shigatoxin producing Escherichia coli in Chilean children: clinical and epidemiological aspects. Rev Chilena Infectol 2008; 25:435-44; PMID:19194606
   PubMed Web of Science ®Google Scholar
• WHO. Scientific Working Group Meeting on Zoonotic Non-0157 Shiga Toxin-Producing Escherichia coli (1998: Berlin G, Unit WHOVPH. Zoonotic Non-0157 Shiga Toxin-Producing Escherichia coli (STEC): report of a WHO scientific working group meeting, Berlin, Germany 23-26 June 1998. Geneva: World Health Organization, 1998.
   Google Scholar
• Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930-6; PMID:10874060; http://dx.doi.org/10.1056/NEJM200006293422601
   PubMed Web of Science ®Google Scholar
• Hurd HS, Malladi S. An outcomes model to evaluate risks and benefits of Escherichia coli vaccination in beef cattle. Foodborne Pathog Dis 2012; 9:952-61; PMID:22989170; http://dx.doi.org/10.1089/fpd.2012.1150
   PubMedGoogle Scholar
• Matthews L, Reeve R, Gally DL, Low JC, Woolhouse MEJ, McAteer SP, Locking ME, Chase-Topping ME, Haydon DT, Allison LJ, et al. Predicting the public health benefit of vaccinating cattle against Escherichia coli O157. Proc Natl Acad Sci USA 2013; 110:16265-70; PMID:24043803; http://dx.doi.org/10.1073/pnas.1304978110
   PubMedGoogle Scholar
• Snedeker KG, Campbell M, Sargeant JM. A systematic review of vaccinations to reduce the shedding of Escherichia coli O157 in the faeces of domestic ruminants. Zoonoses Public Health 2012; 59:126-38; PMID:21824378; http://dx.doi.org/10.1111/j.1863-2378.2011.01426.x
   PubMed Web of Science ®Google Scholar
• Thomas DE, Elliott EJ. Interventions for preventing diarrhea-associated hemolytic uremic syndrome: systematic review. BMC Public Health 2013; 13:799-; PMID:24007265; http://dx.doi.org/10.1186/1471-2458-13-799
   PubMed Web of Science ®Google Scholar
• Varela NP, Dick P, Wilson J. Assessing the existing information on the efficacy of bovine vaccination against Escherichia coli O157:H7–a systematic review and meta-analysis. Zoonoses Public Health 2013; 60:253-68; PMID:22856462; http://dx.doi.org/10.1111/j.1863-2378.2012.01523.x
   PubMedGoogle Scholar
• Renwick SA, Wilson JB, Clarke RC, Lior H, Borczyk AA, Spika J, Rahn K, McFadden K, Brouwer A, Copps A. Evidence of direct transmission of Escherichia coli O157:H7 infection between calves and a human. J Infect Dis 1993; 168:792-3; PMID:8354927; http://dx.doi.org/10.1093/infdis/168.3.792
   PubMed Web of Science ®Google Scholar
• Mohawk KL, O'Brien AD. Mouse models of Escherichia coli O157:H7 infection and shiga toxin injection. J Biomed Biotechnol 2011; 2011:258185; PMID:21274267; http://dx.doi.org/10.1155/2011/258185
   PubMed Web of Science ®Google Scholar
• Garcia-Angulo VA, Kalita A, Torres AG. Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection. Vaccine 2013; 31:3229-35; PMID:23707170; http://dx.doi.org/10.1016/j.vaccine.2013.05.013
   PubMed Web of Science ®Google Scholar
• Asper DJ, Karmali MA, Townsend H, Rogan D, Potter AA. Serological response of Shiga toxin-producing Escherichia coli type III secreted proteins in sera from vaccinated rabbits, naturally infected cattle, and humans. Clin Vaccine Immunol 2011; 18:1052-7; PMID:21593239; http://dx.doi.org/10.1128/CVI.00068-11
   PubMed Web of Science ®Google Scholar
• Greatorex JS, Thorne GM. Humoral immune responses to Shiga-like toxins and Escherichia coli O157 lipopolysaccharide in hemolytic-uremic syndrome patients and healthy subjects. J Clin Microbiol 1994; 32:1172-8; PMID:8051241
   PubMed Web of Science ®Google Scholar
• Jenkins C, Chart H, Smith HR, Hartland EL, Batchelor M, Delahay RM, Dougan G, Frankel G. Antibody response of patients infected with verocytotoxin-producing Escherichia coli to protein antigens encoded on the LEE locus. J Med Microbiol 2000; 49:97-9101; PMID:10628831
   PubMed Web of Science ®Google Scholar
• John M, Kudva IT, Griffin RW, Dodson AW, McManus B, Krastins B, Sarracino D, Progulske-Fox A, Hillman JD, Handfield M, et al. Use of in vivo-induced antigen technology for identification of Escherichia coli O157:H7 proteins expressed during human infection. Infect Immun 2005; 73:2665-79; PMID:15845468; http://dx.doi.org/10.1128/IAI.73.5.2665-2679.2005
   PubMed Web of Science ®Google Scholar
• Li Y, Frey E, Mackenzie AM, Finlay BB. Human response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors. Infect Immun 2000; 68:5090-5; PMID:10948130; http://dx.doi.org/10.1128/IAI.68.9.5090-5095.2000
   PubMed Web of Science ®Google Scholar
• Sherman P, Soni R, Yeger H. Characterization of flagella purified from enterohemorrhagic, vero-cytotoxin-producing Escherichia coli serotype O157:H7. J Clin Microbiol 1988; 26:1367-72; PMID:3045153
   PubMed Web of Science ®Google Scholar
• Horne C, Vallance BA, Deng W, Finlay BB. Current progress in enteropathogenic and enterohemorrhagic Escherichia coli vaccines. Expert Rev Vaccines 2002; 1:483-93; PMID:12901587; http://dx.doi.org/10.1586/14760584.1.4.483
   PubMedGoogle Scholar
• Calderon Toledo C, Arvidsson I, Karpman D. Cross-reactive protection against enterohemorrhagic Escherichia coli infection by enteropathogenic E. coli in a mouse model. Infect Immun 2011; 79:2224-33; PMID:21402761; http://dx.doi.org/10.1128/IAI.01024-10
   PubMedGoogle Scholar
• Keller R, Hilton TD, Rios H, Boedeker EC, Kaper JB. Development of a live oral attaching and effacing Escherichia coli vaccine candidate using Vibrio cholerae CVD 103-HgR as antigen vector. Microb Pathog 2010; 48:1-8; PMID:19878715; http://dx.doi.org/10.1016/j.micpath.2009.10.005
   PubMedGoogle Scholar
• Ishikawa S, Kawahara K, Kagami Y, Isshiki Y, Kaneko A, Matsui H, Okada N, Danbara H. Protection against Shiga toxin 1 challenge by immunization of mice with purified mutant Shiga toxin 1. Infect Immun 2003; 71:3235-9; PMID:12761104; http://dx.doi.org/10.1128/IAI.71.6.3235-3239.2003
   PubMed Web of Science ®Google Scholar
• Marcato P, Mulvey G, Read RJ, Vander Helm K, Nation PN, Armstrong GD. Immunoprophylactic potential of cloned Shiga toxin 2 B subunit. J Infect Dis 2001; 183:435-43; PMID:11133375; http://dx.doi.org/10.1086/318080
   PubMedGoogle Scholar
• Marcato P, Griener TP, Mulvey GL, Armstrong GD. Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia. Infect Immun 2005; 73:6523-9; PMID:16177326; http://dx.doi.org/10.1128/IAI.73.10.6523-6529.2005
   PubMed Web of Science ®Google Scholar
• Smith MJ, Teel LD, Carvalho HM, Melton-Celsa AR, O'Brien AD. Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 2006; 24:4122-9; PMID:16551486; http://dx.doi.org/10.1016/j.vaccine.2006.02.035
   PubMedGoogle Scholar
• Babiuk S, Asper DJ, Rogan D, Mutwiri GK, Potter AA. Subcutaneous and intranasal immunization with type III secreted proteins can prevent colonization and shedding of Escherichia coli O157:H7 in mice. Microb Pathog 2008; 45:7-11; PMID:18487034; http://dx.doi.org/10.1016/j.micpath.2008.01.005
   PubMed Web of Science ®Google Scholar
• Cataldi A, Yevsa T, Vilte DA, Schulze K, Castro-Parodi M, Larzabal M, Ibarra C, Mercado EC, Guzman CA. Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant. Vaccine 2008; 26:5662-7; PMID:18675866; http://dx.doi.org/10.1016/j.vaccine.2008.07.027
   PubMedGoogle Scholar
• Fan H-Y, Wang L, Luo J, Long B-G. Protection against Escherichia coli O157:H7 challenge by immunization of mice with purified Tir proteins. Mol Biol Rep 2012; 39:989-97; PMID:21567195; http://dx.doi.org/10.1007/s11033-011-0824-0
   PubMed Web of Science ®Google Scholar
• McNeilly TN, Mitchell MC, Rosser T, McAteer S, Low JC, Smith DGE, Huntley JF, Mahajan A, Gally DL. Immunization of cattle with a combination of purified intimin-531, EspA and Tir significantly reduces shedding of Escherichia coli O157:H7 following oral challenge. Vaccine 2010; 28:1422-8; PMID:19903545; http://dx.doi.org/10.1016/j.vaccine.2009.10.076
   PubMed Web of Science ®Google Scholar
• Potter AA, Klashinsky S, Li Y, Frey E, Townsend H, Rogan D, Erickson G, Hinkley S, Klopfenstein T, Moxley RA, et al. Decreased shedding of Escherichia coli O157:H7 by cattle following vaccination with type III secreted proteins. Vaccine 2004; 22:362-9; PMID:14670317; http://dx.doi.org/10.1016/j.vaccine.2003.08.007
   PubMed Web of Science ®Google Scholar
• Stanford K, Hannon S, Booker CW, Jim GK. Variable efficacy of a vaccine and direct-fed microbial for controlling Escherichia coli O157:H7 in feces and on hides of feedlot cattle. Foodborne Pathog Dis 2014; 11:379-87; PMID:24673729; http://dx.doi.org/10.1089/fpd.2013.1693
   PubMedGoogle Scholar
• Cheng Y, Feng Y, Luo P, Gu J, Yu S, Zhang W-J, Liu Y-Q, Wang Q-X, Zou Q-M, Mao X-H. Fusion expression and immunogenicity of EHEC EspA-Stx2Al protein: implications for the vaccine development. J Microbiol 2009; 47:498-505; PMID:19763426; http://dx.doi.org/10.1007/s12275-009-0116-8
   PubMedGoogle Scholar
• Gu J, Liu Y, Yu S, Wang H, Wang Q, Yi Y, Zhu F, Yu X-J, Zou Q, Mao X. Enterohemorrhagic Escherichia coli trivalent recombinant vaccine containing EspA, intimin and Stx2 induces strong humoral immune response and confers protection in mice. Microbes Infect 2009; 11:835-41; PMID:19427397; http://dx.doi.org/10.1016/j.micinf.2009.04.024
   PubMed Web of Science ®Google Scholar
• Amani J, Salmanian AH, Rafati S, Mousavi SL. Immunogenic properties of chimeric protein from espA, eae and tir genes of Escherichia coli O157:H7. Vaccine 2010; 28:6923-9; PMID:20709010; http://dx.doi.org/10.1016/j.vaccine.2010.07.061
   PubMed Web of Science ®Google Scholar
• Zhang X-H, He K-W, Zhang S-X, Lu W-C, Zhao P-D, Luan X-T, Ye Q, Wen L-B, Li B, et al. Subcutaneous and intranasal immunization with Stx2B-Tir-Stx1B-Zot reduces colonization and shedding of Escherichia coli O157:H7 in mice. Vaccine 2011; 29:3923-9; PMID:21338683; http://dx.doi.org/10.1016/j.vaccine.2011.02.007
   PubMed Web of Science ®Google Scholar
• Cai K, Gao X, Li T, Wang Q, Hou X, Tu W, Xiao L, Tian M, Liu Y, Wang H. Enhanced immunogenicity of a novel Stx2Am-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 2011; 29:946-52; PMID:21134452; http://dx.doi.org/10.1016/j.vaccine.2010.11.035
   PubMed Web of Science ®Google Scholar
• Bentancor LV, Bilen M, Brando RJF, Ramos MV, Ferreira LCS, Ghiringhelli PD, Palermo MS. A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model. Clin Vaccine Immunol 2009; 16:712-8; PMID:19176691; http://dx.doi.org/10.1128/CVI.00328-08
   PubMedGoogle Scholar
• Shariati Mehr K, Mousavi SL, Rasooli I, Amani J, Rajabi M. A DNA vaccine against Escherichia coli O157:H7. Iran Biomed J 2012; 16:133-9; PMID:23023214
   PubMedGoogle Scholar
• Fujii J, Naito M, Yutsudo T, Matsumoto S, Heatherly DP, Yamada T, Kobayashi H, Yoshida S-I, Obrig T. Protection by a recombinant Mycobacterium bovis Bacillus Calmette-Guerin vaccine expressing Shiga toxin 2 B subunit against Shiga toxin-producing Escherichia coli in mice. Clin Vaccine Immunol 2012; 19:1932-7; PMID:23035176; http://dx.doi.org/10.1128/CVI.00473-12
   PubMed Web of Science ®Google Scholar
• Gu J, Ning Y, Wang H, Xiao D, Tang B, Luo P, Cheng Y, Jiang M, Li N, Zou Q, et al. Vaccination of attenuated EIS-producing Salmonella induces protective immunity against enterohemorrhagic Escherichia coli in mice. Vaccine 2011; 29:7395-403; PMID:21807051; http://dx.doi.org/10.1016/j.vaccine.2011.07.069
   PubMed Web of Science ®Google Scholar
• Oliveira AF, Cardoso SA, Almeida FBdR, de Oliveira LL, Pitondo-Silva A, Soares SG, Hanna ES. Oral immunization with attenuated Salmonella vaccine expressing Escherichia coli O157:H7 intimin gamma triggers both systemic and mucosal humoral immunity in mice. Microbiol Immunol 2012; 56:513-22; PMID:22671942; http://dx.doi.org/10.1111/j.1348-0421.2012.00477.x
   PubMedGoogle Scholar
• Rojas RLG, Gomes PADP, Bentancor LV, Sbrogio-Almeida ME, Costa SOP, Massis LM, Ferreira RCC, Palermo MS, Ferreira LCS. Salmonella enterica serovar Typhimurium vaccine strains expressing a nontoxic Shiga-like toxin 2 derivative induce partial protective immunity to the toxin expressed by enterohemorrhagic Escherichia coli. Clin Vaccine Immunol 2010; 17:529-36; PMID:20147499; http://dx.doi.org/10.1128/CVI.00495-09
   PubMedGoogle Scholar
• Cai K, Gao X, Li T, Hou X, Wang Q, Liu H, Xiao L, Tu W, Liu Y, Shi J, et al. Intragastric immunization of mice with enterohemorrhagic Escherichia coli O157:H7 bacterial ghosts reduces mortality and shedding and induces a Th2-type dominated mixed immune response. Can J Microbiol 2010; 56:389-98; PMID:20555401; http://dx.doi.org/10.1139/W10-025
   PubMedGoogle Scholar
• Mayr UB, Kudela P, Atrasheuskaya A, Bukin E, Ignatyev G, Lubitz W. Rectal single dose immunization of mice with Escherichia coli O157:H7 bacterial ghosts induces efficient humoral and cellular immune responses and protects against the lethal heterologous challenge. Microb Biotechnol 2012; 5:283-94; PMID:22103353; http://dx.doi.org/10.1111/j.1751-7915.2011.00316.x
   PubMedGoogle Scholar
• Vilte DA, Larzabal M, Mayr UB, Garbaccio S, Gammella M, Rabinovitz BC, Delgado F, Meikle V, Cantet RJC, Lubitz P, et al. A systemic vaccine based on Escherichia coli O157:H7 bacterial ghosts (BGs) reduces the excretion of E. coli O157:H7 in calves. Vet Immunol Immunopathol 2012; 146:169-76; PMID:22460171; http://dx.doi.org/10.1016/j.vetimm.2012.03.002
   PubMed Web of Science ®Google Scholar
• Vande Walle K, Vanrompay D, Cox E. Bovine innate and adaptive immune responses against Escherichia coli O157:H7 and vaccination strategies to reduce faecal shedding in ruminants. Vet Immunol Immunopathol 2013; 152:109-20; PMID:23084625; http://dx.doi.org/10.1016/j.vetimm.2012.09.028
   PubMed Web of Science ®Google Scholar
• Van der Woude MW, Baumler AJ. Phase and antigenic variation in bacteria. Clin Microbiol Rev 2004; 17:581-611; PMID:15258095; http://dx.doi.org/10.1128/CMR.17.3.581-611.2004
   PubMed Web of Science ®Google Scholar
• Adu-Bobie J, Frankel G, Bain C, Goncalves AG, Trabulsi LR, Douce G, Knutton S, Dougan G. Detection of intimins alpha, beta, gamma, and delta, four intimin derivatives expressed by attaching and effacing microbial pathogens. J Clin Microbiol 1998; 36:662-8; PMID:9508292
   PubMed Web of Science ®Google Scholar
• Bono JL, Keen JE, Clawson ML, Durso LM, Heaton MP, Laegreid WW. Association of Escherichia coli O157:H7 tir polymorphisms with human infection. BMC Infect Dis 2007; 7:98; PMID:17718910; http://dx.doi.org/10.1186/1471-2334-7-98
   PubMedGoogle Scholar
• China B, Goffaux F, Pirson V, Mainil J. Comparison of eae, tir, espA and espB genes of bovine and human attaching and effacing Escherichia coli by multiplex polymerase chain reaction. FEMS Microbiol Lett 1999; 178:177-82; PMID:10483737; http://dx.doi.org/10.1111/j.1574-6968.1999.tb13775.x
   PubMedGoogle Scholar
• Crepin VF, Shaw R, Knutton S, Frankel G. Molecular basis of antigenic polymorphism of EspA filaments: development of a peptide display technology. J Mol Biol 2005; 350:42-52; PMID:15921692; http://dx.doi.org/10.1016/j.jmb.2005.04.060
   PubMedGoogle Scholar
• Smith DR, Moxley RA, Peterson RE, Klopfenstein TJ, Erickson GE, Bretschneider G, Berberov EM, Clowser S. A two-dose regimen of a vaccine against type III secreted proteins reduced Escherichia coli O157:H7 colonization of the terminal rectum in beef cattle in commercial feedlots. Foodborne Pathog Dis 2009; 6:155-61; PMID:19105625; http://dx.doi.org/10.1089/fpd.2008.0136
   PubMedGoogle Scholar
• Vogstad AR, Moxley RA, Erickson GE, Klopfenstein TJ, Smith DR. Assessment of heterogeneity of efficacy of a three-dose regimen of a type III secreted protein vaccine for reducing STEC O157 in feces of feedlot cattle. Foodborne Pathog Dis 2013; 10:678-83; PMID:23692077; http://dx.doi.org/10.1089/fpd.2012.1374
   PubMedGoogle Scholar
• Thomson DU, Loneragan GH, Thornton AB, Lechtenberg KF, Emery DA, Burkhardt DT, Nagaraja TG. Use of a siderophore receptor and porin proteins-based vaccine to control the burden of Escherichia coli O157:H7 in feedlot cattle. Foodborne Pathog Dis 2009; 6:871-7; PMID:19737063; http://dx.doi.org/10.1089/fpd.2009.0290
   PubMedGoogle Scholar
• Fox JT TD, Drouillard JS, Thornton AB, Burkhardt DT, Emery DA, Nagaraja TG. Efficacy of Escherichia coli O157:H7 siderophore receptor/porin proteins-based vaccine in feedlot cattle naturally shedding E. coli O157. Foodborne Pathog Dis 2009; 6:893-9; PMID:19737065; http://dx.doi.org/10.1089/fpd.2009.0336
   PubMedGoogle Scholar
• Wileman BW TD, Olson KC, Jaeger JR, Pacheco LA, Bolte J, Burkhardt DT, Emery DA, Straub D. Escherichia coli O157:H7 shedding in vaccinated beef calves born to cows vaccinated prepartum with Escherichia coli O157:H7 SRP vaccine. J Food Prot 2011; 74:1599-604; PMID:22004804; http://dx.doi.org/10.4315/0362-028X.JFP-11-034
   PubMedGoogle Scholar
• Cull CA PZ, Nagaraja TG, Bello NM, Babcock AH, Renter DG. Efficacy of a vaccine and a direct-fed microbial against fecal shedding of Escherichia coli O157:H7 in a randomized pen-level field trial of commercial feedlot cattle. Vaccine 2012; 30:6210-5; PMID:22704925; http://dx.doi.org/10.1016/j.vaccine.2012.05.080
   PubMed Web of Science ®Google Scholar
• Wang F YQ, Kase JA, Meng J, Clotilde LM, Lin A, Ge B. Current trends in detecting non-O157 Shiga toxin-producing Escherichia coli in food. Foodborne Pathog Dis 2013; 10:665-77; PMID:23755895; http://dx.doi.org/10.1089/fpd.2012.1448
   PubMed Web of Science ®Google Scholar
• Konadu EY, Parke JC, Tran HT, Bryla DA, Robbins JB, Szu SC. Investigational vaccine for Escherichia coli O157: phase 1 study of O157 O-specific polysaccharide-Pseudomonas aeruginosa recombinant exoprotein A conjugates in adults. J Infect Dis 1998; 177:383-7; PMID:9466525; http://dx.doi.org/10.1086/514203
   PubMedGoogle Scholar
• Ahmed A, Li J, Shiloach Y, Robbins JB, Szu SC. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 2-5-year-old children. J Infect Dis 2006; 193:515-21; PMID:16425130; http://dx.doi.org/10.1086/499821
   PubMed Web of Science ®Google Scholar
• Garcia-Angulo VA, Kalita A, Kalita M, Lozano L, Torres AG. Comparative genomics and immunoinformatics approach for the identification of vaccine candidates for enterohemorrhagic Escherichia coli O157:H7. Infect Immun 2014; 82:2016-26; PMID:24595137; http://dx.doi.org/10.1128/IAI.01437-13
   PubMedGoogle Scholar
• Montero D OP, Gutiérrez D, Araya D, Salazar JC, Prado V, Oñate A, Del Canto F, Vidal R. Immunoproteomic analysis to identify Shiga toxin-producing Escherichia coli outer membrane proteins expressed during human infection. Infect Immun 2014; 82: 4767-77; PMID:25156722; http://dx.doi.org/10.1128/IAI.02030-14
   PubMedGoogle Scholar
• Dasti JI, Tareen AM, Lugert R, Zautner AE, Gross U. Campylobacter jejuni: a brief overview on pathogenicity-associated factors and disease-mediating mechanisms. Int J Med Microbiol 2010; 300:205-11; PMID:19665925; http://dx.doi.org/10.1016/j.ijmm.2009.07.002
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention U. Campylobacter, general information. [Internet] 2014 [Last updated 06/03/2014]. Available from http://www.cdc.gov/nczved/divisions/dfbmd/diseases/Campylobacter/
   Google Scholar
• European Food Safety Authority. Campylobacter [Internet]. 2014 [Last updated 07/14/2014]. Available from http://www.efsa.europa.eu/en/topics/topic/campylobacter.htm
   Google Scholar
• Guerry P, Poly F, Riddle M, Maue AC, Chen Y-H, Monteiro MA. Campylobacter polysaccharide capsules: virulence and vaccines. Front Cell Infect Microbiol 2012; 2:7; PMID:22919599; http://dx.doi.org/10.3389/fcimb.2012.00007
   PubMed Web of Science ®Google Scholar
• De Zoete MR, Van Putten JPM, Wagenaar JA. Vaccination of chickens against Campylobacter. Vaccine 2007; 25:5548-57; PMID:17224215; http://dx.doi.org/10.1016/j.vaccine.2006.12.002
   PubMed Web of Science ®Google Scholar
• Smith CK, Abuoun M, Cawthraw SA, Humphrey TJ, Rothwell L, Kaiser P, Barrow PA, Jones MA. Campylobacter colonization of the chicken induces a proinflammatory response in mucosal tissues. FEMS Immunol Med Microbiol 2008; 54:114-21; PMID:18647351; http://dx.doi.org/10.1111/j.1574-695X.2008.00458.x
   PubMedGoogle Scholar
• Rice BE, Rollins DM, Mallinson ET, Carr L, Joseph SW. Campylobacter jejuni in broiler chickens: colonization and humoral immunity following oral vaccination and experimental infection. Vaccine 1997; 15:1922-32; PMID:9413103; http://dx.doi.org/10.1016/S0264-410X(97)00126-6
   PubMed Web of Science ®Google Scholar
• Noor SM, Husband AJ, Widders PR. In ovo oral vaccination with Campylobacter jejuni establishes early development of intestinal immunity in chickens. Br Poult Sci 1995; 36:563-73; PMID:8590089; http://dx.doi.org/10.1080/00071669508417802
   PubMed Web of Science ®Google Scholar
• Widders PR, Thomas LM, Long KA, Tokhi MA, Panaccio M, Apos E. The specificity of antibody in chickens immunised to reduce intestinal colonisation with Campylobacter jejuni. Vet Microbiol 1998; 64:39-50; PMID:9874102; http://dx.doi.org/10.1016/S0378-1135(98)00251-X
   PubMed Web of Science ®Google Scholar
• Khoury CA, Meinersmann RJ. A genetic hybrid of the Campylobacter jejuni flaA gene with LT-B of Escherichia coli and assessment of the efficacy of the hybrid protein as an oral chicken vaccine. Avian Dis 1995; 39:812-20; PMID:8719215; http://dx.doi.org/10.2307/1592418
   PubMed Web of Science ®Google Scholar
• Monteiro MA, Baqar S, Hall ER, Chen Y-H, Porter CK, Bentzel DE, Applebee L, Guerry P. Capsule polysaccharide conjugate vaccine against diarrheal disease caused by Campylobacter jejuni. Infect Immun 2009; 77:1128-36; PMID:19114545; http://dx.doi.org/10.1128/IAI.01056-08
   PubMed Web of Science ®Google Scholar
• Pawelec D, Rozynek E, Popowski J, Jagusztyn-Krynicka EK. Cloning and characterization of a Campylobacter jejuni 72Dz/92 gene encoding a 30 kDa immunopositive protein, component of the ABC transport system; expression of the gene in avirulent Salmonella typhimurium. FEMS Immunol Med Microbiol 1997; 19:137-50; PMID:9395059; http://dx.doi.org/10.1111/j.1574-695X.1997.tb01083.x
   PubMedGoogle Scholar
• Pawelec DP, Korsak D, Wyszynska AK, Rozynek E, Popowski J, Jagusztyn-Krynicka EK. Genetic diversity of the Campylobacter genes coding immunodominant proteins. FEMS Microbiol Lett 2000; 185:43-9; PMID:10731605; http://dx.doi.org/10.1111/j.1574-6968.2000.tb09038.x
   PubMed Web of Science ®Google Scholar
• Wyszynska A, Raczko A, Lis M, Jagusztyn-Krynicka EK. Oral immunization of chickens with avirulent Salmonella vaccine strain carrying C. jejuni 72Dz/92 cjaA gene elicits specific humoral immune response associated with protection against challenge with wild-type Campylobacter. Vaccine 2004; 22:1379-89; PMID:15063560; http://dx.doi.org/10.1016/j.vaccine.2003.11.001
   PubMed Web of Science ®Google Scholar
• Buckley AM, Wang J, Hudson DL, Grant AJ, Jones MA, Maskell DJ, Stevens MP. Evaluation of live-attenuated Salmonella vaccines expressing Campylobacter antigens for control of C. jejuni in poultry. Vaccine 2010; 28:1094-105; PMID:19853682; http://dx.doi.org/10.1016/j.vaccine.2009.10.018
   PubMed Web of Science ®Google Scholar
• Clark JD, Oakes RD, Redhead K, Crouch CF, Francis MJ, Tomley FM, Blake DP. Eimeria species parasites as novel vaccine delivery vectors: anti-Campylobacter jejuni protective immunity induced by Eimeria tenella-delivered CjaA. Vaccine 2012; 30:2683-8; PMID:22342500; http://dx.doi.org/10.1016/j.vaccine.2012.02.002
   PubMed Web of Science ®Google Scholar